Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.11.14.567145

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in murine model of the SARS-CoV-2-related acute respiratory distress syndrome

Chernov, A.·Rodionov, M.·Kazakov, V.·Ivanova, K.·Mesheryakov, F.·Kudriaeva, A.·Gabibov, A.·Telegin, G.·Belogurov, A.
View original source ↗Export metadata ↓

Abstract

The acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis is one of the main causes of high mortality in patients with COVID-19 (novel coronavirus disease 2019) - ongoing SARS-CoV-2 infection, reached more than 0.7 billion registered cases. Recently we elaborated non- surgical and reproducible method of unilateral total diffuse alveolar damage (DAD) of the left lung in ICR mice - a publicly available imitation of the ARDS caused by SARS-CoV-2. Our data reads that two C-C chemokine receptor 5 (CCR5) ligands - macrophage inflammatory proteins (MIP) - (MIP-1/CCL3) and (MIP-1{beta}/CCL4) are upregulated in this DAD model up to three orders of magnitude compared to the background level. Here we showed that a nonpeptide compound TAK- 779, antagonist of CCR5/CXCR3, readily prevents DAD of the lung with a single injection of 2.5 mg/kg. Histological analysis revealed reduced peribronchial and perivascular mononuclear infiltration in the lung, and mononuclear infiltration of the wall and lumen of the alveoli in the TAK- 779-treated animals. Administration of the TAK-779 decreased 3-5-fold level of serum cytokines and chemokines in animals with DAD, including CCR5 ligands MIP-1/{beta}, MCP-1 and CCL5. Computed tomography revealed rapid recovery of the density and volume of the affected lung in TAK-779- treated animals. Our pre-clinical data suggest that TAK-779 is more effective than administration of dexamethasone or anti-IL6R therapeutic antibody tocilizumab, which brings novel therapeutic modality to TAK-779 and other CCR5 inhibitors recruited in ongoing clinical studies as a potential drugs for treatment of COVID19 and similar virus-induced inflammation syndromes. Abstract summaryThe pathogenesis of the SARS-CoV-2 infection is tightly linked with the cytokine storm resulting in the enormous release of cytokines and chemokines. Its clinical manifestation - the acute respiratory distress syndrome (ARDS), may be caused by self-sustaining hypersensitivity reactions leading to lung collapse even after virus clearance. Here we report that two macrophage inflammatory proteins, MIP-1/CCL3 and MIP-1{beta}/CCL4, seem to orchestrate mononuclear infiltration into the lungs during diffuse alveolar damage (DAD) in ICR mice - our murine model of ARDS caused by SARS-CoV-2. Inhibition of the C-C chemokine receptor 5 (CCR5) - parental receptor for MIP-1 and MIP-1{beta}, by nonpeptide antagonist TAK-779 results in significant amelioration of DAD in terms of reduced mononuclear infiltration into the lung, suppressed cytokine storm and restored physiology of affected lung according to computed tomography data. We suggest that targeted inhibition of CCR5 should be further elucidated as safe and effective approach to overcome severe viral pneumonia in humans.

Source connections

Explore related subjects

pathologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Chernov, A., Rodionov, M., Kazakov, V., Ivanova, K., Mesheryakov, F., Kudriaeva, A., Gabibov, A., Telegin, G., Belogurov, A.. 2023-11-15. CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in murine model of the SARS-CoV-2-related acute respiratory distress syndrome. https://doi.org/10.1101/2023.11.14.567145

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Evaluating the Transferability of Pathology Foundation Models Across Cancer-related H&E Neurodegeneration-related Immunohistochemical Classification Tasks

Foundation models (FMs) have rapidly become dominant in artificial intelligence and are increasingly being adopted in computational pathology. Numerous pathology-specific FMs have been developed and evaluated for a variety of downstream tasks, most commonly using frozen image embeddings with linear probes. While a pathology FM, at least implicitly suggests broad reusability across tasks, the transferability of these models to neurodegenerative disease-related tasks remains largely unexplored. In this study, we evaluated fourteen frozen feature extractors, including general-vision and pathology FMs, across four pathology image classification datasets spanning two specialized neurodegenerative disease immuno-histochemistry (IHC) tasks (Tau neurofibrillary tangle (NFT) and amyloid-{beta} plaque classification) and two cancer-related hematoxylin and eosin (H&E) tasks (the breast tissue BACH dataset and the multi-tissue TIL dataset). The cancer-related H&E datasets represent tasks more closely aligned with the predominant pretraining domain of many current pathology FMs, whereas the neurodegenerative IHC datasets represent a more specialized domain with limited representation in existing FM pretraining cohorts. Frozen embedding linear probes were compared against a conventional supervised ResNet-50 convolutional neural network (CNN) trained directly on image tiles using identical train, validation, and test splits. Across both neurodegenerative IHC datasets, the supervised CNN substantially outperformed all frozen FM linear probes. In contrast, pathology FMs achieved performance comparable to, and in some cases exceeding, the supervised CNN across the two cancer-related H&E datasets, with UNI2-h achieving the highest performance on BACH and several pathology FMs performing on par with the CNN on the larger TIL dataset. Furthermore, a supervised CNN trained using only 1% of the Tau NFT training data (1,938 tiles) still exceeded the performance of the best frozen FM linear probe trained on the complete dataset. Together, these results suggest the transferability of frozen pathology FMs may depend strongly on how well the downstream task is represented by their pretraining domain. These findings demonstrate frozen pathology FMs transfer effectively to the cancer-related H&E tasks evaluated here but may be less effective for specialized neurodegenerative IHC tasks less well represented in current FM pretraining cohorts. Expanding pathology FM pretraining datasets to include a broader range of disease domains and staining modalities may therefore improve transferability to specialized pathology applications. Our findings also highlight the continued importance of conventional supervised learning and motivate future work investigating nonlinear probes and end-to-end FM fine-tuning.

pathology↗
bioRxiv2026

Keto-gluconeogenic metabolic axis mirrors renal homeostasis and post-injury response in spatial transcriptomics

Metabolic disturbance is a key feature in acute kidney injury (AKI) and chronic kidney disease (CKD). The kidney highly depends on fatty acid metabolism; how renal cells rewire metabolism upon AKI and CKD transition remained unclear. Here, we combine spatial transcriptomics with biochemical analyses to characterize metabolic changes and intercellular interactions during AKI to CKD transition. Using aristolochic acid model of CKD, we spatio-temporally correlated changes in structure and function with metabolic profile during AKI to CKD transition. Surprisingly, keto-gluconeogenic metabolic axis was highly enriched in healthy kidney and paralleled injury phase transitions. Intercellular interaction analysis associated a subtype of macrophage with the drift to chronicity. Online scRNAseq datasets analysis confirmed altered keto-gluconeogenic metabolic pathways in ischemia-reperfusion injured mouse kidneys and AKI and CKD human kidney biopsies compared to healthy controls. This study identifies a metabolic axis transcriptionally mirroring renal homeostasis and injury responses, and tubulo-interstitial interactions that can be targeted to mitigate AKI to CKD transition.

pathology↗
bioRxiv2026

Identification of Novel Inhibitors of JEV RdRp as Potent Antiviral Drugs: Targeting NS5-NS3 Protein Interaction

Japanese Encephalitis Virus (JEV) belongs to the Flavivirus family, and the RNA dependent RNA polymerase (RdRp) domain located at the C terminus of non structural protein 5 (NS5) regulates de novo viral genome synthesis. The conserved priming loop inserted in the thumb domain of RDRP initiates de novo genome synthesis. Interestingly, the reported replication process initiates with an interaction between NS5 (methyltransferase/RDRP) and NS3 (protease/helicase), and inhibiting this interaction directly correlates with the inhibition of viral replication. The function of the priming loop in the context of the NS5 NS3 interaction is not yet known. In this study, we studied the priming loop function in the NS5 NS3 interaction and viral replication. Using a structure based drug design approach, we screened the Maybridge compound library against the RdRp priming loop and identified 15 candidate compounds based on binding energy. Among them, DSHS00151 showed significant dose dependent inhibition of the NS5 NS3 interaction with an IC50 of 3.5 micromolar in the mammalian two hybrid assay, inhibited viral infectivity with an IC50 of 2.54 micromolar, and reduced viral RNA load with an IC50 of 2.9 micromolar, compared to CD10712. Molecular Dynamics (MD) simulations revealed that DSHS00151 exhibits stronger and more stable binding with the priming loop residues (790 to 812) compared to CD10712. The molecular mechanism suggested by the docking of the NS5 and NS3 proteins showed that the priming loop tends to rotate toward the NS3 protein to stabilize the complex, and compound binding restricts this loop rotation, thus compromising the stability of the NS5 and NS3 complex and affecting viral replication. Overall, our study validated the function of the NS5 priming loop as an allosteric site, and compounds binding to this allosteric site belong to the Non Nucleoside Reverse Transcriptase Inhibitors (NNRTI) class of inhibitors, which disrupt the NS5 and NS3 interaction and could be developed as novel anti JEV therapeutics.

pathology↗